Table 1.
Description of the population at inclusion (n = 39).
| Overall Population n = 39 (%) |
n = Patients Whose Data Was Known | |
|---|---|---|
| Sex | ||
| Female | 22 (56.4) | 39 |
| Male | 17 (43.6) | 39 |
| Age (yr) median [IQR25–75] | 25.6 [23.1; 31.7] | 39 |
| Adults (age ≥ 18 yr) | 36 (92.3) | 39 |
| Children (age < 18 yr) | 3 (7.7) | 39 |
| Genetic Subtype | ||
| Deletion | 23 (59) | 39 |
| Disomy | 13 (33.3) | 39 |
| Translocation 15; 17 | 1 (2.3) | 39 |
| Abnormal methylation without further precision | 2 (5.1) | 39 |
| Neonatal Data | ||
| Prematurity (birth < 37 GW) | 7 (25) | 28 |
| Small for gestational age | 9 (33.3) | 27 |
| Age (months) at PWS—median [IQR25–75] | 29 [3,8; 157] | 32 |
| Followed by a Pediatric Team | 29 (85.3) | 34 |
| Duration of Diabetes (yr) median [IQR25–75] | 9.9 [4.3; 12.3] | 38 |
| Endocrine Comorbidities | ||
| GH treatment throughout life | 21 (58.3) | 36 |
| Thyrotropic insufficiency | 16 (42.1) | 38 |
| Corticotropic insufficiency | 2 (5.6) | 36 |
| Hypogonadism | 35 (94.6) | 37 |
| Metabolic Comorbidities | ||
| Hypertension treated or having been treated | 18 (56.3) | 32 |
| Hypertriglyceridemia (TG > 1.5 g/L) | 22 (56.4) | 39 |
| HDL cholesterol < 0.4 g/L | 22 (59.4) | 37 |
| Psychiatric Comorbidities | ||
| Psychiatric hospitalization | 14 (48.3) | 29 |
| Medications | ||
| Number of medications per patient—median [IQR25–75] | 6 [4.5; 7] | 39 |
| Diabetes medications | ||
| Metformin | 29 (82.9) | 35 |
| GLP-1 agonists | 17 (51.5) | 33 |
| Insulin | 19 (50) | 38 |
| Sulfonamides | 7 (20.6) | 34 |
| DPP-4 inhibitors | 3 (8.8) | 32 |
| Meglitinides | 3 (8.8) | 34 |
| SGLT-2 inhibitors | 6 (16.7) | 38 |
| Endocrine medications | ||
| Growth hormone | 6 (16.2) | 37 |
| Levothyroxine | 13 (35.1) | 37 |
| Hydrocortisone | 2 (5.6) | 36 |
| Testosterone for boys | 11 (64.7) | 17 |
| Estroprogestatives for girls | 12 (54.6) | 22 |
| Psychotropic medications | 20 (52.6) | 38 |
| Antipsychotic drugs of all generations | 18 (47.4) | 38 |
| 1st-generation antipsychotic drugs | 9 (24.3) | 37 |
| 2nd-generation antipsychotic drugs | 15 (38.5) | 39 |
| Benzodiazepines | 5 (13.9) | 36 |
| Selective serotonin reuptake inhibitors | 12 (32.4) | 37 |
Data are expressed as Number (%) or Median [IQR], yr: years, GW: weeks of gestation, PWS: Prader-Willi syndrome, GH: growth hormone, TG: triglycerides, HDL: high-density lipoproteins, DPP4: dipeptidyl peptidase-4, GLP-1: glucose-like peptide 1, SGLT-2: sodium/glucose cotransporter 2.